Published in Drug Week, September 2nd, 2005
Additional analyses will be conducted with the data from the phase III study, also known as ETHECC (evaluation of THYMITAQ in hepatocellular carcinoma), to better understand the results of the survival analysis and future activities.
Eximias Pharmaceutical Corp. has an experienced management team and a strong cash position, having completed a $63.5 million financing round in 2004, and is continuing to evaluate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.